New research published in the Journal of Investigative Dermatology (JID) confirms findings of benzene presence and formation in benzoyl peroxide (BPO) drug and acne products—this time, with testing conducted at room temperature.

The latest round of benzene news follows the initial detection of high levels of benzene found in certain BPO-containing acne products announced on March 6, 2024. With the first detection of benzene, Valisure, LLC, an independent testing laboratory, filed a petition with the FDA requesting a recall of products affected by the elevated levels of benzene to allow regulators to investigate.

The new study reports that "111 BPO drug products tested from major US retailers appear to be substantially contaminated with benzene when tested shortly after being acquired off the shelf."

Researchers acquired BPO products from major retail stores in several US states, conducting sampling in California, Connecticut, Florida, Illinois, New York, and Texas.

Read more at Dermatology Times >>